{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:24:44Z","timestamp":1777710284977,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04765-9","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T20:08:48Z","timestamp":1769544528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Finerenone as an add-on treatment to conventional therapies for the patients with diabetic kidney disease"],"prefix":"10.1186","volume":"27","author":[{"given":"Satoshi","family":"Kidoguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sugano","family":"Naoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"6","key":"4765_CR1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1053\/j.ajkd.2017.10.026","volume":"71","author":"K Umanath","year":"2018","unstructured":"Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018;71(6):884\u201395","journal-title":"Am J Kidney Dis"},{"issue":"10225","key":"4765_CR2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GCKD Collaboration","year":"2020","unstructured":"Collaboration GCKD. Global, regional, and national burden of chronic kidney disease, 1990-2017. A systematic analysis for the Global burden of disease study 2017. Lancet. 2020;395(10225):709\u201333","journal-title":"Lancet"},{"issue":"12","key":"4765_CR3","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u201369","journal-title":"N Engl J Med"},{"issue":"12","key":"4765_CR4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851\u201360","journal-title":"N Engl J Med"},{"issue":"9","key":"4765_CR5","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese society of Hypertension guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235\u2013481","journal-title":"Hypertens Res"},{"issue":"24","key":"4765_CR6","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 Diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306","journal-title":"N Engl J Med"},{"issue":"15","key":"4765_CR7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346","journal-title":"N Engl J Med"},{"issue":"2","key":"4765_CR8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327","journal-title":"N Engl J Med"},{"issue":"3","key":"4765_CR9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamainternmed.2024.7381","volume":"185","author":"K Bonnesen","year":"2025","unstructured":"Bonnesen K, Heide-J\u00f8rgensen U, Christensen DH, Christiansen CF, Lash TL, Hennessy S, et al. Effectiveness of empagliflozin vs Dapagliflozin for kidney outcomes in type 2 Diabetes. JAMA Intern Med. 2025;185(3):314\u201323","journal-title":"JAMA Intern Med"},{"issue":"Suppl 1","key":"4765_CR10","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/ndt\/gfz264","volume":"35","author":"CCJ Dekkers","year":"2020","unstructured":"Dekkers CCJ, Gansevoort RT. Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease? Nephrol Dial Transpl. 2020;35(Suppl 1):i33\u201342","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4765_CR11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/biomedicines13010053","volume":"13","author":"K Miyasako","year":"2024","unstructured":"Miyasako K, Maeoka Y, Masaki T. Recent advances and perspectives on the use of mineralocorticoid receptor antagonists for the treatment of Hypertension and chronic kidney disease: a review. Biomedicines. 2024;13(1):53","journal-title":"Biomedicines"},{"issue":"23","key":"4765_CR12","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 Diabetes. N Engl J Med. 2020;383(23):2219\u201329","journal-title":"N Engl J Med"},{"issue":"24","key":"4765_CR13","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 Diabetes. N Engl J Med. 2021;385(24):2252\u201363","journal-title":"N Engl J Med"},{"issue":"6","key":"4765_CR14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional Care in patients with type 2 Diabetes and albuminuria. Circulation. 2024;149(6):450\u201362","journal-title":"Circulation"},{"issue":"10","key":"4765_CR15","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/ndt\/gfaf064","volume":"40","author":"MH Chuang","year":"2025","unstructured":"Chuang MH, Wang HY, Kan WC, Chien CC, Jiang MY, Huang YT, et al. Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD. Nephrol Dial Transpl. 2025;40(10):1897\u2013905","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"4765_CR16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. Finerenone with empagliflozin in chronic kidney disease and type 2 Diabetes. N Engl J Med. 2025;393(6):533\u201343","journal-title":"N Engl J Med"},{"issue":"6","key":"4765_CR17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"4765_CR18","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc23-S011","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 11. Chronic kidney disease and risk Management: standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S191\u2013202","journal-title":"Diabetes Care"},{"issue":"2","key":"4765_CR19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.jhh.1001307","volume":"16","author":"T Tanaka","year":"2002","unstructured":"Tanaka T, Okamura T, Miura K, Kadowaki T, Ueshima H, Nakagawa H, et al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. J Hum Hypertens. 2002;16(2):97\u2013103","journal-title":"J Hum Hypertens"},{"issue":"3","key":"4765_CR20","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s12020-024-03945-7","volume":"86","author":"K Venkatesan","year":"2024","unstructured":"Venkatesan K, Cheryeth MMJ, Verghese AT, Mathews AM, Ravisankar N, Unnikrishnan P, et al. Finerenone and diabetic renal disease: a narrative review. Endocrine. 2024;86(3):882\u201389","journal-title":"Endocrine"},{"issue":"8","key":"4765_CR21","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1172\/JCI43124","volume":"121","author":"S Shibata","year":"2011","unstructured":"Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest. 2011;121(8):3233\u201343","journal-title":"J Clin Invest"},{"issue":"1","key":"4765_CR22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69\u201378","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"4765_CR23","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41440-025-02175-2","volume":"48","author":"A Sato","year":"2025","unstructured":"Sato A, Nishimoto M. Real-world use of finerenone in patients with chronic kidney disease and type 2 diabetes based on large-scale clinical studies: FIDELIO-DKD and FIGARO-DKD. Hypertens Res. 2025;48(6):1929\u201338","journal-title":"Hypertens Res"},{"issue":"9","key":"4765_CR24","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884\u201394","journal-title":"JAMA"},{"issue":"12","key":"4765_CR25","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, et al. Finerenone in patients with chronic kidney disease and type 2 Diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care. 2022;45(12):2991\u201398","journal-title":"Diabetes Care"},{"issue":"12","key":"4765_CR26","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","volume":"176","author":"R Agarwal","year":"2023","unstructured":"Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, et al. Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 Diabetes: a mediation analysis. Ann Intern Med. 2023;176(12):1606\u201316","journal-title":"Ann Intern Med"},{"issue":"4","key":"4765_CR27","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","volume":"38","author":"JB Green","year":"2023","unstructured":"Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, McGill JB, et al. Design of the COmbinatioN effect of FInerenone and EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint study (CONFIDENCE). Nephrol Dial Transpl. 2023;38(4):894\u2013903","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"4765_CR28","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"K Ando","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T, et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(12):944\u201353","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"4765_CR29","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2215\/CJN.09110914","volume":"10","author":"L D\u2019Elia","year":"2015","unstructured":"D\u2019Elia L, Rossi G, Schiano di Cola M, Savino I, Galletti F, Strazzullo P. Meta-analysis of the effect of dietary sodium restriction with or without concomitant Renin-angiotensin-aldosterone system-inhibiting treatment on albuminuria. Clin J Am Soc Nephrol. 2015;10(9):1542\u201352","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"4765_CR30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","volume":"42","author":"A Nishiyama","year":"2019","unstructured":"Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertens Res. 2019;42(3):293\u2013300","journal-title":"Hypertens Res"},{"issue":"10","key":"4765_CR31","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1007\/s12325-022-02282-3","volume":"39","author":"S Ichikawa","year":"2022","unstructured":"Ichikawa S, Tsutsumi J, Sugimoto K, Yamakawa S. Antihypertensive effect of long-term monotherapy with esaxerenone in patients with essential Hypertension: relationship between baseline urinary sodium excretion and its antihypertensive effect. Adv Ther. 2022;39(10):4779\u201391","journal-title":"Adv Ther"},{"issue":"4","key":"4765_CR32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41440-023-01519-0","volume":"47","author":"T Katsuya","year":"2024","unstructured":"Katsuya T, Inobe Y, Uchiyama K, Nishikawa T, Hirano K, Kato M, et al. Exploratory study on the relationship between urinary sodium\/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK study. Hypertens Res. 2024;47(4):835\u201348","journal-title":"Hypertens Res"},{"issue":"12","key":"4765_CR33","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","volume":"79","author":"LM Ruilope","year":"2022","unstructured":"Ruilope LM, Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, et al. Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 Diabetes. Hypertension. 2022;79(12):2685\u201395","journal-title":"Hypertension"},{"issue":"1","key":"4765_CR34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.kint.2025.03.018","volume":"108","author":"SD Navaneethan","year":"2025","unstructured":"Navaneethan SD, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, et al. Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis. Kidney Int. 2025;108(1):136\u201344","journal-title":"Kidney Int"},{"issue":"2","key":"4765_CR35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","volume":"80","author":"SJ Leon","year":"2022","unstructured":"Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, Sucha E, et al. Hyperkalemia-related discontinuation of Renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study. Am J Kidney Dis. 2022;80(2):164\u201373.e1","journal-title":"Am J Kidney Dis"},{"key":"4765_CR36","doi-asserted-by":"crossref","unstructured":"Kdigo GK. Clinical practice guideline for the evaluation and Management of chronic kidney disease. Kidney Int. 2024. 2024;105(4S):S117\u2013314","DOI":"10.1016\/j.kint.2023.10.018"},{"issue":"31","key":"4765_CR37","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363","journal-title":"Eur Heart J"},{"issue":"10","key":"4765_CR38","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/ndt\/gfaf098","volume":"40","author":"A Idowu","year":"2025","unstructured":"Idowu A, Lo KB, Adebolu O, Hamilton M, Abdelmaseeh P, Navaneethan SD, et al. Hyperkalemia risk of finerenone versus spironolactone in CKD patients with type 2 Diabetes. Nephrol Dial Transpl. 2025;40(10):1996\u201399","journal-title":"Nephrol Dial Transpl"},{"issue":"8","key":"4765_CR39","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","volume":"33","author":"M Provenzano","year":"2022","unstructured":"Provenzano M, Puchades MJ, Garofalo C, Jongs N, D\u2019Marco L, Andreucci M, et al. Albuminuria-lowering effect of Dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. J Am Soc Nephrol. 2022;33(8):1569\u201380","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4765_CR40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","volume":"7","author":"P Rossing","year":"2022","unstructured":"Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. Finerenone in predominantly advanced CKD and Type 2 Diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7(1):36\u201345","journal-title":"Kidney Int Rep"},{"issue":"3","key":"4765_CR41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2215\/CJN.0000000000000300","volume":"19","author":"BF Palmer","year":"2024","unstructured":"Palmer BF, Clegg DJ. SGLT2 inhibition and kidney potassium homeostasis. Clin J Am Soc Nephrol. 2024;19(3):399\u2013405","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4765_CR42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, et al. Hyperkalemia risk with Finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol. 2022;33(1):225\u201337","journal-title":"J Am Soc Nephrol"},{"key":"4765_CR43","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Anker SD, Palmer BF, Pitt B, Rossing P, Ruilope LM, et al. Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme. Eur Heart J. 2025","DOI":"10.1093\/eurheartj\/ehaf258"},{"issue":"6","key":"4765_CR44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/a-1134-4980","volume":"52","author":"S Gruber","year":"2020","unstructured":"Gruber S, Beuschlein F. Hypokalemia and the prevalence of primary aldosteronism. Horm Metab Res. 2020;52(6):347\u201356","journal-title":"Horm Metab Res"},{"issue":"6","key":"4765_CR45","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.ajkd.2013.07.013","volume":"62","author":"H Fisher","year":"2013","unstructured":"Fisher H, Hsu CY, Vittinghoff E, Lin F, Bansal N. Comparison of associations of urine protein-creatinine ratio versus albumin-creatinine ratio with complications of CKD: a cross-sectional analysis. Am J Kidney Dis. 2013;62(6):1102\u201308","journal-title":"Am J Kidney Dis"},{"key":"4765_CR46","doi-asserted-by":"crossref","unstructured":"Fuwa D, Fukuda M, Ogiyama Y, Sato R, Mizuno M, Miura T, et al. Addition of hydrochlorothiazide to angiotensin receptor blocker therapy can achieve a lower sodium balance with no acceleration of intrarenal renin angiotensin system in patients with chronic kidney disease. J Renin Angiotensin Aldosterone Syst. 2016;17(2):1470320316652032","DOI":"10.1177\/1470320316652032"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04765-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04765-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04765-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:14:26Z","timestamp":1771420466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04765-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4765"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04765-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of The Jikei University School of Medicine (No. 37\u2013041). Consent to participate from each individual participant was waived because an opt-out approach was applied in this study in accordance with the rules in the Ethics Committee of The Jikei University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication from each individual participant was waived because an opt-out approach was applied in this study in accordance with the rules in the Ethics Committee of The Jikei University School of Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no competing interests regarding this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}